Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

medtronic plc - MDT

MDT

Close Chg Chg %
85.01 -0.93 -1.09%

Pre-Market

84.08

-0.93 (1.09%)

Volume: 7.39M

Last Updated:

Nov 20, 2024, 3:59 PM EDT

Trade Now

Company Overview: medtronic plc - MDT

MDT Key Data

Open

$84.86

 Day Range

83.55 - 84.98

52 Week Range

75.96 - 92.68

 Market Cap

$109.01B

Shares Outstanding

1.28B

 Public Float

1.28B

Beta

0.85

 Rev. Per Employee

N/A

P/E Ratio

25.92

 EPS

$3.28

Yield

327.06%

 Dividend

$0.70

EX-DIVIDEND DATE

Sep 27, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

6.44M

  

MDT Performance

1 Week
 
 -2.89%
 
1 Month
 
 -7.85%
 
3 Months
 
 -3.79%
 
1 Year
 
 7.64%
 
5 Years
 
 -23.30%
 

MDT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 35
Full Ratings ➔

About medtronic plc - MDT

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

MDT At a Glance

Medtronic Plc
Parkmore Business Park West
Galway, Galway 2
Phone 353-1-438-1700 Revenue 32.36B
Industry Medical Specialties Net Income 3.68B
Sector Health Technology 2024 Sales Growth 3.641%
Fiscal Year-end 04 / 2025 Employees 95,000
View SEC Filings

MDT Valuation

P/E Current 25.915
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 28.855
Price to Sales Ratio 3.277
Price to Book Ratio 2.082
Price to Cash Flow Ratio 15.628
Enterprise Value to EBITDA 14.837
Enterprise Value to Sales 3.841
Total Debt to Enterprise Value 0.21

MDT Efficiency

Revenue/Employee 340,673.684
Income Per Employee 38,694.737
Receivables Turnover 5.281
Total Asset Turnover 0.358

MDT Liquidity

Current Ratio 2.033
Quick Ratio 1.55
Cash Ratio 0.742

MDT Profitability

Gross Margin 60.107
Operating Margin 17.711
Pretax Margin 14.946
Net Margin 11.358
Return on Assets 4.063
Return on Equity 7.229
Return on Total Capital 4.82
Return on Invested Capital 4.847

MDT Capital Structure

Total Debt to Total Equity 51.872
Total Debt to Total Capital 34.155
Total Debt to Total Assets 28.947
Long-Term Debt to Equity 49.333
Long-Term Debt to Total Capital 32.483
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Medtronic Plc - MDT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
30.12B 31.69B 31.23B 32.36B
Sales Growth
+4.16% +5.21% -1.45% +3.64%
Cost of Goods Sold (COGS) incl D&A
12.14B 11.76B 12.32B 12.91B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.70B 2.71B 2.70B 2.65B
Depreciation
919.00M 974.00M 999.00M 954.00M
Amortization of Intangibles
1.78B 1.73B 1.70B 1.69B
COGS Growth
+10.10% -3.10% +4.77% +4.77%
Gross Income
17.98B 19.92B 18.90B 19.45B
Gross Income Growth
+0.51% +10.82% -5.12% +2.90%
Gross Profit Margin
+59.70% +62.88% +60.54% +60.11%
2021 2022 2023 2024 5-year trend
SG&A Expense
12.45B 12.78B 12.94B 13.36B
Research & Development
2.49B 2.65B 2.70B 2.73B
Other SG&A
9.95B 10.13B 10.24B 10.62B
SGA Growth
+1.41% +2.69% +1.24% +3.24%
Other Operating Expense
155.00M 956.00M 455.00M 364.00M
Unusual Expense
1.22B 596.00M 729.00M 1.03B
EBIT after Unusual Expense
4.16B 5.59B 4.78B 4.70B
Non Operating Income/Expense
357.00M 479.00M 1.17B 852.00M
Non-Operating Interest Income
- 192.00M 386.00M 597.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
617.00M 553.00M 583.00M 719.00M
Interest Expense Growth
-9.13% -10.37% +5.42% +23.33%
Gross Interest Expense
617.00M 553.00M 583.00M 719.00M
Interest Capitalized
- - - -
-
Pretax Income
3.90B 5.52B 5.36B 4.84B
Pretax Income Growth
-3.95% +41.64% -2.77% -9.82%
Pretax Margin
+12.93% +17.41% +17.18% +14.95%
Income Tax
265.00M 456.00M 1.58B 1.13B
Income Tax - Current - Domestic
287.00M 467.00M 1.30B 756.00M
Income Tax - Current - Foreign
439.00M 599.00M 530.00M 905.00M
Income Tax - Deferred - Domestic
(626.00M) (402.00M) (336.00M) (435.00M)
Income Tax - Deferred - Foreign
165.00M (209.00M) 83.00M (93.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
3.63B 5.06B 3.78B 3.70B
Minority Interest Expense
24.00M 22.00M 26.00M 28.00M
Net Income
3.61B 5.04B 3.76B 3.68B
Net Income Growth
-24.70% +39.77% -25.44% -2.18%
Net Margin Growth
+11.97% +15.91% +12.03% +11.36%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
3.61B 5.04B 3.76B 3.68B
Preferred Dividends
- - - -
-
Net Income Available to Common
3.61B 5.04B 3.76B 3.68B
EPS (Basic)
2.6812 3.7537 2.826 2.7687
EPS (Basic) Growth
-24.94% +40.00% -24.71% -2.03%
Basic Shares Outstanding
1.34B 1.34B 1.33B 1.33B
EPS (Diluted)
2.6632 3.7287 2.8196 2.7635
EPS (Diluted) Growth
-24.86% +40.01% -24.38% -1.99%
Diluted Shares Outstanding
1.35B 1.35B 1.33B 1.33B
EBITDA
8.08B 8.89B 8.21B 8.38B
EBITDA Growth
+7.16% +10.07% -7.72% +2.08%
EBITDA Margin
+26.83% +28.07% +26.28% +25.89%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 95.20
Number of Ratings 35 Current Quarters Estimate 1.362
FY Report Date 01 / 2025 Current Year's Estimate 5.451
Last Quarter’s Earnings 1.26 Median PE on CY Estimate N/A
Year Ago Earnings 5.20 Next Fiscal Year Estimate 5.845
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 28 28 30 30
Mean Estimate 1.36 1.61 5.45 5.84
High Estimates 1.38 1.63 5.48 5.95
Low Estimate 1.35 1.59 5.39 5.75
Coefficient of Variance 0.47 0.71 0.30 0.85

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 11 11 10
OVERWEIGHT 6 5 5
HOLD 16 16 17
UNDERWEIGHT 0 0 0
SELL 2 2 2
MEAN Overweight Overweight Overweight

Insider Actions for Medtronic Plc - MDT

Date Name Shares Transaction Value
Aug 20, 2024 Gary Louis Corona Interim CFO 33,035 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 12, 2024 Geoffrey Straub Martha Chairman and CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 12, 2024 Geoffrey Straub Martha Chairman and CEO; Director 1,594 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 12, 2024 Geoffrey Straub Martha Chairman and CEO; Director 143,348 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $83.82 per share 12,015,429.36
Jun 12, 2024 Geoffrey Straub Martha Chairman and CEO; Director 144,942 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $83.76 per share 12,140,341.92
Jun 12, 2024 Geoffrey Straub Martha Chairman and CEO; Director 162,461 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $62.76 per share 10,196,052.36
Jun 12, 2024 Geoffrey Straub Martha Chairman and CEO; Director 160,867 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $62.76 per share 10,096,012.92
May 6, 2024 Kendall J. Powell Director 45,843 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $80.89 per share 3,708,240.27
May 6, 2024 Elizabeth G. Nabel Director 15,674 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $80.89 per share 1,267,869.86
May 6, 2024 Andrea J. Goldsmith Director 8,306 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $80.89 per share 671,872.34
May 6, 2024 Lidia L. Fonseca Director 3,682 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $80.89 per share 297,836.98
May 6, 2024 Kevin E. Lofton Director 6,230 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $80.89 per share 503,944.70
May 6, 2024 Craig Arnold Director 38,275 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $80.89 per share 3,096,064.75
May 6, 2024 Denise M. O'Leary Director 77,057 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $80.89 per share 6,233,140.73
May 6, 2024 Randall J. Hogan Director 45,088 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $80.89 per share 3,647,168.32
May 6, 2024 Scott C. Donnelly Director 19,604 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $80.89 per share 1,585,767.56
May 2, 2024 Gregory P. Lewis Director 1,821 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $80.86 per share 147,246.06
Apr 10, 2024 Michael Marinaro EVP & President, Surgical OU 27,925 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $83.14 per share 2,321,684.50
Dec 15, 2023 Brett Wall EVP & Pres Neuroscience 33,907 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $79.27 per share 2,687,807.89
Dec 15, 2023 Ivan K. Fong EVP GENERAL COUNSEL & SECR 39,201 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $79.35 per share 3,110,599.35

Medtronic Plc in the News